Biogen Idec is in the news again; on July 4, 2013 the company presented new data in support of clinical and safety profile for ELOCTATE, its candidate for hemophilia A that it is developing in ...

Global stockout halts access to Hemgenix gene therapy, delaying treatment for adults with hemophilia B amid manufacturing challenges.

KING OF PRUSSIA, Pa., June 20, 2023 /PRNewswire/ -- Global biotechnology leader CSL Behring today announced that the first patient has received U.S. Food and Drug Administration (FDA) approved ...

Five-year clinical study results show this revolutionary one-time treatment allowed 94% of patients to stop routine factor IX prophylaxis DETROIT, March 23, 2026 /PRNewswire/ -- The Barbara Ann ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

Add Yahoo as a preferred source to see more of our stories on Google. A Michigan man is the first patient in the state, outside of clinical trials, to receive a new gene therapy for hemophilia A at ...

In an open letter to the Hemophilia B Community, CSL Limited vice president medical affairs, Dr Deborah Long shared an ...

The Barbara Ann Karmanos Cancer Institute in Detroit has become the first and only independent cancer center in the U.S. to ...

Hemophilia may lead to internal bleeding, particularly in joints and the brain, which could cause pain, swelling, and neurological symptoms. Preventive treatment with clotting factor concentrates and ...

Blood clotting represents one of the body’s most elegant and complex protective mechanisms. This intricate process involves numerous proteins working in precise sequence – often described as a ...

The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...